SCHEMBL6248971

SCHEMBL6248971

CC(=O)Oc1ccccc1CCCCCCCSCCCCCCCc1ccccc1OC(C)=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.53
PPARA Q07869 1/20 0.53
PTGS2 P35354 15/20 0.52
THRA P10827 1/20 0.51
THRB P10828 1/20 0.51
NPC1 O15118 1/20 0.43
LMNA P02545 1/20 0.43
PKM P14618 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
ESR1 P03372 1/20 0.42
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
HMGB1 P09429 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
GGT1 P19440 1/20 0.42
PTGS1 P23219 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6247832 1.00 PPARG (0.53) PPARGPPARAPTGS2THRATHRB
SCHEMBL6249982 1.00 PPARG (0.53) PPARGPPARAPTGS2THRATHRB
SCHEMBL6534979 1.00 PPARG (0.53) PPARGPPARAPTGS2THRATHRB
SCHEMBL6535016 1.00 PPARG (0.53) PPARGPPARAPTGS2THRATHRB
SCHEMBL6248486 0.98 PTGS2 (0.51) PPARGPPARAPTGS2THRATHRB
SCHEMBL6251319 0.94 PTGS2 (0.51) PPARGPPARAPTGS2THRATHRB
SCHEMBL16065424 0.89 PPARG (0.59) PPARGPPARAPTGS2THRATHRB
SCHEMBL6250163 0.87 PTGS2 (0.53) PPARGPPARAPTGS2KDM4EALDH1A1
SCHEMBL7637671 0.84 PPARA (0.72) PPARGPPARAPTGS2THRATHRB
SCHEMBL3043813 0.84 PPARA (0.72) PPARGPPARAPTGS2THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0958275-A4 SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 UNIV VANDERBILT (US) 2004-12-01 EP claimed
US-6284918-B1 ENZYME INHIBITORS VANDERBILT UNIVERSITY 2001-09-04 US claimed
EP-0958275-A1 SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 VANDERBILT UNIVERSITY (US) 1999-11-24 EP claimed
US-5973191-A AN ACETOXYPHENYLALKYL SULFIDE, SALT OR HYDRATE VANDERBILT UNIVERSITY (US) 1999-10-26 US claimed
WO-1998029382-A1 SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 VANDERBILT UNIVERSITY (US) 1998-07-09 WO claimed
EP-1194141-B1 ANTIVIRAL THERAPY UNIV MEDISCH CENTRUM UTRECHT (NL) 2005-08-17 EP disclosed
US-20050059745-A1 Antiviral therapy MARIA NOTTET JOHANNES SERVATIU (NL) 2005-03-17 US disclosed
EP-0958275-A4 SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 UNIV VANDERBILT (US) 2004-12-01 EP disclosed
WO-2004076687-A1 METHOD FOR DETERMINING ANTIVIRAL ACTIVITY OF AHPS RELATED COMPOUNDS UNIVERSITEIT UTRECHT HOLDING B.V. (NL) 2004-09-10 WO disclosed
US-6787573-B2 THERAPY FOR DRUG RESISTANT VIRUS UNIVERSITEIT UTRECHT (NL) 2004-09-07 US disclosed
EP-1452605-A1 Method for determining antiviral activity Universiteit Utrecht Holding B.V. (NL) 2004-09-01 EP disclosed
EP-1263429-B1 ANTIVIRAL THERAPY UNIV UTRECHT (NL) 2004-07-14 EP disclosed
EP-1194141-A1 ANTIVIRAL THERAPY Universitair Medisch Centrum Utrecht (NL) 2002-04-10 EP disclosed
WO-2001068086-A1 ANTIVIRAL THERAPY UNIVERSITEIT UTRECHT (NL) 2001-09-20 WO disclosed
US-6284918-B1 ENZYME INHIBITORS VANDERBILT UNIVERSITY 2001-09-04 US disclosed
WO-2001001985-A1 ANTIVIRAL THERAPY UNIVERSITAIR MEDISCH CENTRUM UTRECHT (NL) 2001-01-11 WO disclosed
EP-1064940-A1 Antiviral therapy Universitair Medisch Centrum Utrecht (NL) 2001-01-03 EP disclosed
EP-0958275-A1 SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 VANDERBILT UNIVERSITY (US) 1999-11-24 EP disclosed
US-5973191-A AN ACETOXYPHENYLALKYL SULFIDE, SALT OR HYDRATE VANDERBILT UNIVERSITY (US) 1999-10-26 US disclosed
WO-1998029382-A1 SELECTIVE INHIBITORS OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2 VANDERBILT UNIVERSITY (US) 1998-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059745-A1 Antiviral therapy ZC3HAV1, EIF2AK2, MAVS PPARG 2141/4885PPARA 1906/4885PTGS2 4159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.